8 unknown, 1 completed. 8 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Unknown 7, Completed 1 |
| Phase 1 | 5 | Unknown 4, Completed 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Huiqiang Huang: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma Orelabrutinib, Thiotepa - Refractory and Relapsed Primary CNS Lymphoma, PCNSL | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 29 | 2021-12-01 | 2021-08-26 |
| Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL PD-1 Antibody, Lenalidomide - Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 30 | 2021-03-31 | 2021-03-15 |
| Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma Methotrexate, Ibrutinib, Temozolomide - Primary Central Nervous System Lymphoma, PCNSL | Phase 2 | Unknown | Huiqiang Huang | 33 | 2020-10-10 | 2022-04-07 |
| Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL Camrelizumab, Apatinib - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 33 | 2020-07-23 | 2021-03-15 |
| Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma Toripalimab, Rituximab, R-CHOP Protocol - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 140 | 2020-04-24 | 2022-04-14 |
| Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma Rituximab Biosimilar, Pegylated Interferon α-2b - Lymphoma, B-Cell | Phase 2 | Unknown | Huiqiang Huang | 52 | 2020-01-15 | 2022-04-07 |
| Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL Sintilimab, Chidamide - Safety and Efficacy | Phase 1 / Phase 2 | Completed | Huiqiang Huang | 40 | 2019-03-29 | 2022-04-14 |
| Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation Chidamide BIW, Chidamide QD - Lymphoma, Extranodal NK-T-Cell, EBV | Phase 2 | Unknown | Huiqiang Huang | 24 | 2016-09-01 | 2016-08-25 |
| PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma pegaspargase, Gemcitabine, Oxaliplatin - Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type | Phase 3 | Unknown | Huiqiang Huang | 264 | 2013-04-25 | 2021-03-15 |
Pyloric Stenosis, Hypertrophic (3) · Recurrence (3) · Lymphoma, Extranodal NK-T-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Non-Hodgkin (2) · Lymphoma, B-Cell (1)
Methotrexate (2) · Dexamethasone (1) · Gemcitabine (1) · Lenalidomide (1) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · Oxaliplatin (1) · R-CHOP protocol (1) · Rituximab (1) · Temozolomide (1) · Thalidomide (1) · Thiotepa (1) · apatinib (1) · camrelizumab (1) · ibrutinib (1) · orelabrutinib (1)
China (8)